Industry Newsdupilumaballergic fungal rhinosinusitisphase 3u.s. approval
Dupixent Receives U.S. Approval For AFRS
5.6
Relevance Score
The U.S. approved Dupixent (dupilumab) as the first and only treatment for allergic fungal rhinosinusitis (AFRS). Approval in adults and children aged 6 years and older is supported by a Phase 3 trial showing significant reductions in nasal signs and symptoms.
Scoring Rationale
Clinical approval significance drives score, but niche scope and RSS-only limited source reduce impact despite Phase 3 support.
Sources
- Read OriginalDupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS)manilatimes.net
